Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis

Journal of Clinical Investigation

Volumn 127, Issue 10, 2017, Pages 3675-3688

  Wei, Ying ^a   Kim, Thomas J ^a   Peng, David H ^b   Duan, Dana ^a   Gibbons, Don L ^b   Yamauchi, Mitsuo ^c   Jackson, Julia R ^a   Le Saux, Claude J ^a,d   Calhoun, Cheresa ^d   Peters, Jay ^d   Derynck, Rik ^a   Backes, Bradley J ^a   Chapman, Harold A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHIN; COLLAGEN; CORILAGIN; ELLAGIC ACID; ELLAGITANNIN; LYSYL OXIDASE LIKE 2; LYSYL OXIDASE LIKE 3; OXIDOREDUCTASE; POLYPHENOL DERIVATIVE; PROTEIN SERINE THREONINE KINASE; PROTEIN SNAIL1; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1 RECEPTOR KINASE; TRIHYDROXYPHENOLIC COMPOUND; UNCLASSIFIED DRUG; ENZYME INHIBITOR; LOXL2 PROTEIN, HUMAN; LOXL2 PROTEIN, MOUSE; PHENOL DERIVATIVE; PROTEIN KINASE INHIBITOR; TGF-BETA TYPE I RECEPTOR; TGFB1 PROTEIN, HUMAN; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUTOOXIDATION; CANCER CELL; CONFERENCE PAPER; CONTROLLED STUDY; CROSS LINKING; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; FIBROGENESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; LUNG FIBROSIS; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL; A-549 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY; PULMONARY FIBROSIS;

A549 CELLS; AMINO ACID OXIDOREDUCTASES; ANIMALS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PHENOLS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PULMONARY FIBROSIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85030571617     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI94624     Document Type: Conference Paper

References (59)

1. Thannickal VJ, Zhou Y, Gaggar A, Duncan SR. Fibrosis: ultimate and proximate causes. J Clin Invest. 2014;124(11):4673-4677.
2. Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med. 2013;5(167):167sr1.
3. Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest. 2004;125(2):754-765.
4. Han CY, et al. Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt. Nat Commun. 2016;7:13817.
5. Hu C, et al. Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFβ1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem. 2008;283(16):10226-10231.
6. Sheppard D. Transforming growth factor β: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc. 2006;3(5):413-417.
7. Principe DR, et al. TGFβ signaling in the pancreatic tumor microenvironment promotes fibrosis and immune evasion to facilitate tumorigenesis. Cancer Res. 2016;76(9):2525-2539.
8. Kaminski N, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A. 2000;97(4):1778-1783.
9. Levental KR, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139(5):891-906.
10. Cox TR, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 2013;73(6):1721-1732.
11. Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol. 2010;22(5):697-706.
12. Sheppard D. Integrin-mediated activation of latent transforming growth factor β. Cancer Metastasis Rev. 2005;24(3):395-402.
13. Chang TT, Thakar D, Weaver VM. Forcedependent breaching of the basement membrane. Matrix Biol. 2017;57-58:178-189.
14. Vázquez PF, et al. TGF-β specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer. Clin Exp Metastasis. 2013;30(8):993-1007.
15. Fernandez IE, Eickelberg O. The impact of TGF-β on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc. 2012;9(3):111-116.
16. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004;3(12):1011-1022.
17. Neuzillet C, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015;147:22-31.
18. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790-811.
19. Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol. 2014;32:51-82.
20. Mordasky Markell L, Pérez-Lorenzo R, Masiuk KE, Kennett MJ, Glick AB. Use of a TGFβ type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFβ signaling in tumor promotion and progression. Carcinogenesis. 2010;31(12):2127-2135.
21. Lacouture ME, et al. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008). Cancer Immunol Immunother. 2015;64(4):437-446.
22. Anderton MJ, et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol. 2011;39(6):916-924.
23. Herbertz S, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-β signaling pathway. Drug Des Devel Ther. 2015;9:4479-4499.
24. Blackwell TS, et al. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med. 2014;189(2):214-222.
25. Bandyopadhyay A, Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets. 2009;10(7):645-652.
26. Xi Y, et al. Inhibition of epithelial-to-mesenchymal transition and pulmonary fibrosis by methacycline. Am J Respir Cell Mol Biol. 2014;50(1):51-60.
27. Sriram N, Kalayarasan S, Manikandan R, Arumugam M, Sudhandiran G. Epigallocatechin gallate attenuates fibroblast proliferation and excessive collagen production by effectively intervening TGF-β1 signalling. Clin Exp Pharmacol Physiol. 2015;42(8):849-859.
28. Wang Z, et al. Corilagin attenuates aerosol bleomycin-induced experimental lung injury. Int J Mol Sci. 2014;15(6):9762-9779.
29. Peng DH, et al. ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis. Oncogene. 2017;36(14):1925-1938.
30. Peinado H, et al. A molecular role for lysyl oxidaselike 2 enzyme in snail regulation and tumor progression. EMBO J. 2005;24(19):3446-3458.
31. Erler JT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440(7088):1222-1226.
32. Sethi A, Mao W, Wordinger RJ, Clark AF. Transforming growth factor-β induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52(8):5240-5250.
33. Finney J, Moon HJ, Ronnebaum T, Lantz M, Mure M. Human copper-dependent amine oxidases. Arch Biochem Biophys. 2014;546:19-32.
34. Kagan HM, Trackman PC. Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol. 1991;5(3):206-210.
35. Yamauchi M, Sricholpech M. Lysine posttranslational modifications of collagen. Essays Biochem. 2012;52:113-133.
36. Chen CZ, et al. The Scar-in-a-Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single well. Br J Pharmacol. 2009;158(5):1196-1209.
37. Chen CZ, Raghunath M. Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis state of the art. Fibrogenesis Tissue Repair. 2009;2:7.
38. Hecker L, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med. 2009;15(9):1077-1081.
39. Chen Y, et al. Lysyl hydroxylase 2 is secreted by tumor cells and can modify collagen in the extracellular space. J Biol Chem. 2016;291(50):25799-25808.
40. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitortype 1 gene. EMBO J. 1998;17(11):3091-3100.
41. Raghu G, et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med. 2017;5(1):22-32.
42. Hornstra IK, Birge S, Starcher B, Bailey AJ, Mecham RP, Shapiro SD. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J Biol Chem. 2003;278(16):14387-14393.
43. Mäki JM, et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation. 2002;106(19):2503-2509.
44. Mäki JM, Sormunen R, Lippo S, Kaarteenaho-Wiik R, Soininen R, Myllyharju J. Lysyl oxidase is essential for normal development and function of the respiratory system and for the integrity of elastic and collagen fibers in various tissues. Am J Pathol. 2005;167(4):927-936.
45. Liu X, et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet. 2004;36(2):178-182.
46. Peter B, Bosze S, Horvath R. Biophysical characteristics of proteins and living cells exposed to the green tea polyphenol epigallocatechin-3-gallate (EGCg): review of recent advances from molecular mechanisms to nanomedicine and clinical trials. Eur Biophys J. 2017;46(1):1-24.
47. Mereles D, Hunstein W. Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci. 2011;12(9):5592-5603.
48. Zhang HM, Zhao L, Li H, Xu H, Chen WW, Tao L. Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol Med. 2014;11(2):92-100.
49. Stoner GD, et al. Pharmacokinetics of anthocyanins and ellagic acid in healthy volunteers fed freeze-dried black raspberries daily for 7 days. J Clin Pharmacol. 2005;45(10):1153-1164.
50. Mertens-Talcott SU, Jilma-Stohlawetz P, Rios J, Hingorani L, Derendorf H. Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem. 2006;54(23):8956-8961.
51. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D. Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr. 2006;136(10):2481-2485.
52. Lee MJ, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin- 3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev. 2002;11(10 pt 1):1025-1032.
53. Nagle DG, Ferreira D, Zhou YD. Epigallocatechin- 3-gallate (EGCG): chemical and biomedical perspectives. Phytochemistry. 2006;67(17):1849-1855.
54. Liu J, et al. Association of green tea consumption with mortality from all-cause, cardiovascular disease and cancer in a Chinese cohort of 165,000 adult men. Eur J Epidemiol. 2016;31(9):853-865.
55. Lustosa BB, et al. Green tea (Cammellia sinensis) attenuates ventricular remodeling after experimental myocardial infarction. Int J Cardiol. 2016;225:147-153.
56. Kuriyama S, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006;296(10):1255-1265.
57. Chapman HA, et al. Integrin α6β4 identifies an adult distal lung epithelial population with regenerative potential in mice. J Clin Invest. 2011;121(7):2855-2862.
58. Henderson NC, et al. Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013;19(12):1617-1624.
59. Yamauchi M, Shiiba M. Lysine hydroxylation and cross-linking of collagen. Methods Mol Biol. 2008;446:95-108.